Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

Michelle A. Elliott, Ayalew Tefferi

Research output: Contribution to journalArticle

335 Citations (Scopus)

Abstract

Despite decades of clinical and laboratory research, relatively little has been accomplished concerning the pathogenesis as well as the identification of risk factors for thrombosis and bleeding in myeloproliferative disorders. In polycythaemia vera, the pro-thrombotic effect of an elevated haematocrit is well established. In contrast, thrombocytosis per se has not been similarly incriminated in essential thrombocythaemia. In both conditions, advanced age and the presence of a prior event identify thrombosis-prone patients. There is increasing evidence to suggest an additional role by leucocytes that might partly explain the antithrombotic effects of myelosuppressive therapy. A substantial minority of affected patients display reduced levels of high molecular weight von Willebrand protein in the plasma during extreme thrombocytosis and it is believed that this might explain the bleeding diathesis of such patients. Recent controlled studies support the therapeutic value of hydroxyurea and aspirin in essential thrombocythaemia and polycythaemia vera, respectively. The current communication will address the incidence, phenotype, pathogenesis, risk factors, prevention, and treatment of both thrombosis and haemorrhage in these disorders.

Original languageEnglish (US)
Pages (from-to)275-290
Number of pages16
JournalBritish Journal of Haematology
Volume128
Issue number3
DOIs
StatePublished - Feb 2005

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Thrombocytosis
Thrombosis
Hemorrhage
Myeloproliferative Disorders
Hydroxyurea
Disease Susceptibility
von Willebrand Factor
Hematocrit
Aspirin
Leukocytes
Therapeutics
Molecular Weight
Communication
Phenotype
Incidence
Research

Keywords

  • Essential thrombocythaemia
  • Haemorrhage
  • Polycythaemia vera
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. / Elliott, Michelle A.; Tefferi, Ayalew.

In: British Journal of Haematology, Vol. 128, No. 3, 02.2005, p. 275-290.

Research output: Contribution to journalArticle

@article{345b1c7e8d2248f882bf9f087961207f,
title = "Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia",
abstract = "Despite decades of clinical and laboratory research, relatively little has been accomplished concerning the pathogenesis as well as the identification of risk factors for thrombosis and bleeding in myeloproliferative disorders. In polycythaemia vera, the pro-thrombotic effect of an elevated haematocrit is well established. In contrast, thrombocytosis per se has not been similarly incriminated in essential thrombocythaemia. In both conditions, advanced age and the presence of a prior event identify thrombosis-prone patients. There is increasing evidence to suggest an additional role by leucocytes that might partly explain the antithrombotic effects of myelosuppressive therapy. A substantial minority of affected patients display reduced levels of high molecular weight von Willebrand protein in the plasma during extreme thrombocytosis and it is believed that this might explain the bleeding diathesis of such patients. Recent controlled studies support the therapeutic value of hydroxyurea and aspirin in essential thrombocythaemia and polycythaemia vera, respectively. The current communication will address the incidence, phenotype, pathogenesis, risk factors, prevention, and treatment of both thrombosis and haemorrhage in these disorders.",
keywords = "Essential thrombocythaemia, Haemorrhage, Polycythaemia vera, Thrombosis",
author = "Elliott, {Michelle A.} and Ayalew Tefferi",
year = "2005",
month = "2",
doi = "10.1111/j.1365-2141.2004.05277.x",
language = "English (US)",
volume = "128",
pages = "275--290",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

AU - Elliott, Michelle A.

AU - Tefferi, Ayalew

PY - 2005/2

Y1 - 2005/2

N2 - Despite decades of clinical and laboratory research, relatively little has been accomplished concerning the pathogenesis as well as the identification of risk factors for thrombosis and bleeding in myeloproliferative disorders. In polycythaemia vera, the pro-thrombotic effect of an elevated haematocrit is well established. In contrast, thrombocytosis per se has not been similarly incriminated in essential thrombocythaemia. In both conditions, advanced age and the presence of a prior event identify thrombosis-prone patients. There is increasing evidence to suggest an additional role by leucocytes that might partly explain the antithrombotic effects of myelosuppressive therapy. A substantial minority of affected patients display reduced levels of high molecular weight von Willebrand protein in the plasma during extreme thrombocytosis and it is believed that this might explain the bleeding diathesis of such patients. Recent controlled studies support the therapeutic value of hydroxyurea and aspirin in essential thrombocythaemia and polycythaemia vera, respectively. The current communication will address the incidence, phenotype, pathogenesis, risk factors, prevention, and treatment of both thrombosis and haemorrhage in these disorders.

AB - Despite decades of clinical and laboratory research, relatively little has been accomplished concerning the pathogenesis as well as the identification of risk factors for thrombosis and bleeding in myeloproliferative disorders. In polycythaemia vera, the pro-thrombotic effect of an elevated haematocrit is well established. In contrast, thrombocytosis per se has not been similarly incriminated in essential thrombocythaemia. In both conditions, advanced age and the presence of a prior event identify thrombosis-prone patients. There is increasing evidence to suggest an additional role by leucocytes that might partly explain the antithrombotic effects of myelosuppressive therapy. A substantial minority of affected patients display reduced levels of high molecular weight von Willebrand protein in the plasma during extreme thrombocytosis and it is believed that this might explain the bleeding diathesis of such patients. Recent controlled studies support the therapeutic value of hydroxyurea and aspirin in essential thrombocythaemia and polycythaemia vera, respectively. The current communication will address the incidence, phenotype, pathogenesis, risk factors, prevention, and treatment of both thrombosis and haemorrhage in these disorders.

KW - Essential thrombocythaemia

KW - Haemorrhage

KW - Polycythaemia vera

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=13444256042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444256042&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.05277.x

DO - 10.1111/j.1365-2141.2004.05277.x

M3 - Article

C2 - 15667529

AN - SCOPUS:13444256042

VL - 128

SP - 275

EP - 290

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -